Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective diligently but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my last few shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire interview that I came away with a bad impression of the company.

Irony of irony, my bad impression of the business has grown steadily, however, the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the technology as well as associated intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) along with the first new drug program approval ($five million), and also royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and numerous therapies, it’s this single treatment and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, several illness sorts, multiple presentations and multiple publications.

Can all of it be smoke and mirrors? That’s a question I’ve been asking myself through the really beginning of the interest of mine in this business. Judging by the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a traditional battleground, or maybe some may say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *